Introduction
============

The ability of cells to migrate is a fundamental process in all living organisms. In vertebrates, cell migration is required for a wide array of biological processes that include embryogenesis, angiogenesis, epithelial wound healing, and immune responses. It is also involved in pathological conditions, such as arthritis, vascular disease, and neoplastic invasion ([@bib105]; [@bib131]). Cell migration has been well characterized in *Drosophila melanogaster* and *Caenorhabditis elegans*, where it is indispensable for their development ([@bib85]; [@bib91]). In addition, in the social amoeba *Dictyostelium discoideum*, directed cell migration or chemotaxis is essential for cells to aggregate into a mound that will later differentiate into a multicellular organism ([@bib6]). In order for cells to move, they must first acquire a polarized morphology where F-actin is primarily enriched at the front and myosin II is assembled on the sides and at the back ([@bib7]). Then, the polarized cells undergo a highly coordinated cycle of protrusions and retractions that are coupled with traction provided by the formation and release of adhesive contacts with the substrate ([@bib75]). Not surprisingly, to accommodate the wide array of biological processes that depend on cell migration, the protrusion/retraction cycle is specifically regulated in different cell types. For example, slow-moving mesenchymal cells like fibroblasts exhibit strong cell--substrate adhesion forces that develop into mature contacts and give rise to slow migration speeds and almost no cell deformability ([@bib33]; [@bib97]). On the other hand, fast-moving amoeboid cells like leukocytes and *Dictyostelium discoideum* exhibit weak and sparse adhesion to substrates, and, as a result, migrate orders of magnitude faster and show remarkable plasticity ([@bib121]). Regardless of the mode of migration used, during directed cell migration, cells must be able to determine where and when protrusions, retractions, and adhesions have to occur to migrate to the correct location. This is established by extracellular cues that act through receptor tyrosine kinase (RTK) and G protein--coupled receptor (GPCR) signal transduction pathways, which provide spatio-temporal information to direct the distribution of cytoskeletal elements and establish cell polarity ([@bib22]; [@bib6]). Although Rho family GTP-binding proteins are important for regulating actin assembly to form protrusions, such as lamellipodia and filopodia, as well as force traction through actomyosin contractility, it is the upstream RTK and GPCR effectors that ultimately regulate the activity of Rho GTP-binding proteins ([@bib55]; [@bib42]; [@bib11]). In the past few years, our understanding of the signal transduction pathways that link receptors to Rho GTP-binding proteins has broadened to include products of phosphoinositide 3-kinase (PI3K), phospholipase A~2~ (PLA~2~), phospholipase C (PLC), adenylyl cyclase, and guanylyl cyclase ([@bib6]; [@bib119]; [@bib66]; [@bib129]; [@bib121]). More recently, another highly conserved signaling component, the Ser/Thr protein kinase TOR (target of rapamycin), has also been shown to transduce migration signals to cytoskeletal elements. In this review, we highlight data linking TOR to the regulation of cell migration and chemotaxis.

TORC1 and TORC2: evolutionarily conserved signaling complexes
=============================================================

TOR, initially identified in *Saccharomyces cerevisiae* ([@bib43]; [@bib16]), is a member of the phosphatidylinositol kinase--related kinase (PIKK) family, which includes ATM (ataxia-telangiectasia mutated), ATR (ATM and Rad3-related), DNA-dependent protein kinase (DNA-PK), and hSMG1 (suppressor with morphological effect on genitalia) ([@bib46]; [@bib1]). These kinases possess Ser/Thr protein kinase activity and do not display lipid kinase activity ([@bib14]; [@bib15]). TOR is a large (290 kD) multi-domain protein ([Table I](#tbl1){ref-type="table"}) that is structurally and functionally conserved from yeast to mammals. Its name arises from the fact that TOR binds the bacterial macrolide rapamycin when it is complexed with FKBP12---a peptidyl prolyl isomerase ([@bib43]; [@bib68]). FKBP12--rapamycin binds to the FKBP12--rapamycin-binding domain of TOR ([Table I](#tbl1){ref-type="table"}), which inhibits TOR activity. Single amino acid substitutions in this domain block binding of FKBP12--rapamycin and generate a rapamycin-resistant form of TOR ([@bib43]; [@bib19]; [@bib88]).
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TOR exists in two functionally distinct multiprotein complexes named TOR complex 1 (TORC1) and TORC2. Each complex is highly conserved from yeast to mammals and is composed of specific core components and interactors (see [Box 1](#box1){ref-type="boxed-text"} and recent reviews on the topic; [@bib52]; [@bib140]). The precise role of each component of TORC1 and TORC2 has yet to be fully understood. In mTORC1, LST8 has been proposed to act as a signal receiver ([@bib65]), whereas Raptor functions as a scaffold for recruiting mTORC1 substrates, and PRAS40 and Deptor appear to be negative regulators ([@bib32]; [@bib130]; [@bib102]). In mTORC2, LST8 is required for the full catalytic kinase activity of mTOR and to a lesser extent, for structural stability of the complex ([@bib39]). Rictor and mSin1 interact with each other and also appear to be important for the structural integrity of mTORC2 ([@bib135]; [@bib54]; [@bib136]). As in mTORC1, Deptor negatively regulates mTORC2 activity ([@bib102]). The function of Protor, a Rictor-binding component that lacks obvious functional domains, remains to be determined ([@bib98]; [@bib134]).

Signaling upstream of TOR complexes
===================================

TORC1 regulates cell growth and metabolism ([@bib74]) and the pathways regulating the activity of mTORC1, which mostly focus on the GTPase-activating protein (GAP) tuberin, have been extensively studied. Tuberin is part of the hamartin/tuberin (TSC1/TSC2) complex and acts as a suppressor of mTORC1 activity ([@bib48]; [@bib47]). It inhibits the GTP-binding protein Rheb (Ras homologue enriched in brain), which directly binds to the mTOR kinase domain and activates mTORC1 by an unknown mechanism ([@bib35]; [@bib49]; [@bib123]; [@bib8]). The activity of tuberin is regulated by inputs from growth factors, nutrients, and hypoxia, and involves Akt ([@bib48]), ERK1/2 ([@bib84]), RSK ([@bib106]), GSK3 ([@bib51]), AMP-dependent kinase, and HIF-1/REDD1 ([@bib50], [@bib51]; [@bib118]; [Box 1](#box1){ref-type="boxed-text"}).

###### 

Conserved core components and interactors of TORC1 and TORC2 in *S. cerevisiae, D. discoideum,* and mammals
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In contrast to mTORC1, the signaling pathways that lead to mTORC2 activation are not well characterized. The TSC1/TSC2 complex physically associates with mTORC2 and positively regulates its activity independently of the Rheb-GAP activity of TSC1/TSC2 ([@bib47]). However, in *Drosophila melanogaster*, Rheb has been reported to negatively regulate dTORC2 through a dTORC1 and dS6K-dependent negative feedback loop ([@bib137]). In addition and similarly to mTORC1, phospholipase D and its metabolite phosphatidic acid appear to be critical for the formation of mTORC2 ([@bib124]). Also, Rac1 was shown to directly interact with mTOR and regulate both mTORC1 and mTORC2 activity ([@bib107]), and PIP~3~ (phosphatidylinositol 3,4,5-trisphosphate), the product of PI3K, has been shown to directly stimulate mTORC2 kinase activity ([@bib34]). However, reports are few and far between and no clear signaling pathway leading to the activation of mTORC2 has emerged. On the other hand, an extensive body of work in *Dictyostelium discoideum* has revealed how chemotactic signals mediated through GPCRs specifically regulate TORC2 activity through G proteins and Ras signals, independently of PI3K ([@bib77]; [@bib61]; [@bib17]). In this organism, a Ras signaling complex, composed of two Ras GEFs (guanine exchange factor; Aimless and RasGEFH), a protein phosphatase (PP2A), and a scaffold designated Sca1, regulates the activation of RasC, which controls the chemoattractant-induced activation of TORC2 at the leading edge of chemotaxing cells ([@bib61]; [@bib18]). In addition, the membrane localization of the Sca1--RasGEF--PP2A complex is regulated through the Akt(PKB)-dependent phosphorylation of Sca1, which provides negative feedback to RasC and TORC2 ([@bib18]). In this system, therefore, a clear path can be traced from a GPCR to the spatio-temporal activation of TORC2, which is important in regulating chemotaxis.

Signaling downstream of TOR complexes
=====================================

The best-characterized TOR substrates include a subgroup of related AGC (cAMP-dependent, cGMP-dependent, and protein kinase C) family kinases ([@bib52]; [@bib99]). AGC kinases are activated by phosphorylation of a conserved Ser/Thr residue in their activation loop (also called T-loop), which can occur via autophosphorylation or through other protein kinases such as PDK1 (3-phosphoinositide--dependent protein kinase 1) ([@bib92]). In addition to phosphorylation at the T-loop motif, several AGC kinases are also phosphorylated at Ser or Thr residues within their hydrophobic motif in the C terminus ([@bib52]; [@bib3]). From yeast to mammals, TOR complexes have been shown to phosphorylate a subset of AGC kinases at a conserved noncatalytic residue within their C-terminal hydrophobic motif, which consists of Phe-X-X-Phe-Ser/Thr-Tyr ([@bib52]; [@bib3]). mTORC1 phosphorylates the hydrophobic motif of S6K1, whereas mTORC2 phosphorylates the hydrophobic motif of SGK1, Akt, and PKC ([@bib100]; [@bib109], [@bib110]; [@bib36]). Similarly, in *Dictyostelium discoideum*, TORC2 phosphorylates the Akt homologues PKBA and PKBR1 ([@bib61]).

A wide array of non-AGC kinases, transcription factors, and other regulators act as effectors of TOR in yeast and mammals ([Box 1](#box1){ref-type="boxed-text"}). Notably, mTORC1 controls the phosphorylation state of 4E-BP1, an important translation initiation machinery component ([@bib41]; [@bib9]; [@bib64]). Phosphorylation of 4E-BP1 induces its dissociation from eIF4E and promotes the initiation of protein translation ([@bib41])---a main effect of mTORC1 activation. In addition, mTORC1 directly phosphorylates and inactivates MAF1 (a key repressor or RNA polymerase II transcription) and contributes to RNA polymerase III--dependent transcription ([@bib62]; [@bib90]; [@bib117]). Interestingly, mTORC1 also regulates microtubule dynamics by physically interacting with CLIP-170, the human homologue of yeast Bik1p, which belongs to a family of conserved microtubule-associated proteins ([@bib21]; [@bib56]). Phosphorylation of CLIP-170 by mTORC1 positively regulates the association of CLIP-170 with microtubules, which enhances their assembly, elongation, and stability. Finally, a few reports have suggested the existence of cross talk between mTORC1 and mTORC2, as S6K1 has been reported to phosphorylate Rictor and positively regulate mTORC2. Although this phosphorylation event does not affect mTORC2 integrity or in vitro kinase activity, it causes an increase in 14-3-3 binding to Rictor and mTORC2-dependent phosphorylation of Akt on S473 ([@bib27]; [@bib57]; [@bib125]). As Akt can positively regulate mTORC1 (see previous section), these findings underscore a potential cross talk between mTORC1 and mTORC2.

TORC1 and cell migration
========================

Studies using rapamycin have implicated mTORC1 as a regulator of mammalian cell migration under normal conditions as well as in the context of tumor metastasis ([Fig. 1](#fig1){ref-type="fig"}). In aortic smooth muscle cells, rapamycin inhibits fibronectin-induced activation of mTORC1 and S6K1 and markedly diminishes chemotaxis of smooth muscle cells toward fibronectin ([@bib103]; [@bib108]), thereby implicating mTORC1 in matrix protein--induced cell migration. Further, mTORC1 regulates growth factor--induced cell migration, as rapamycin treatment inhibits growth factor--induced cell migration of a wide array of cell lines ([@bib5]; [@bib10]; [@bib132]; [@bib128]; [@bib78], [@bib79], [@bib81]; [@bib139]). Interestingly, the rapamycin-mediated inhibition of IGF-I--stimulated motility of Rh30 (rhabdomyosarcoma) cells can be prevented by either the expression of a rapamycin-resistant mutant of mTOR (mTORrr), a constitutively active version of S6K1, or the down-regulation of 4E-BP1 ([@bib78]). Therefore, mTORC1 can regulate cell motility via both S6K1 and 4E-BP1 pathways.

![**mTORC1 and cell migration.** S6K1 and 4E-BP1 control cell motility by regulating (1) F-actin reorganization, (2) focal adhesion formation, (3) MMP-9 up-regulation (4) Rho expression and activity, and (5) VEGF and TGF-β expression in various cell types.](JCB_201102090_RGB_Fig1){#fig1}

Although the mechanisms by which mTORC1 regulates cell migration remain to be determined, a few reports provide evidence that S6K1 controls cell migration by regulating: (a) F-actin reorganization, (b) focal adhesion formation, (c) tissue remodeling through the proteolytical digestion of extracellular matrix via up-regulation of MMP-9 (matrix metalloproteinase 9; [@bib127]; [@bib63]), and (d) Rho expression and activity ([Fig. 1](#fig1){ref-type="fig"}). Activated mTOR and S6K1 along with PI3K, Akt1, and PDK1 are enriched in actin arcs, a caveolin-enriched cytoskeletal structure located at the leading edge of migrating Swiss 3T3 cells, and mTOR and p70S6K activation is required for actin arc formation ([@bib10]). On the other hand, in Rh30 cells, down-regulation of Raptor or S6K1 suppresses IGF-I--stimulated tyrosine phosphorylation of FAK and paxillin ([@bib79]). Thus, the kinase activity of S6K1 seems essential for IGF-I--stimulated focal adhesion formation. In SKOV-3 and CaOV-3 ovarian cancer cells, the expression of a constitutively active form of S6K1 induces MMP-9 expression and enhances its activity, which is independent of de novo protein synthesis as it is not affected by cycloheximide treatment ([@bib139]). In contrast, the effects of 4E-BP1 on cell migration appear to be mediated through changes in mRNA translation and protein synthesis. In activated CD4^+^ T cells, the chemokine CCL5-induced mTOR-dependent phosphorylation of 4E-BP1 ultimately leads to its release from eIF4E. eIF4E associates with the scaffold proteins eIF4G and eIF4A and forms the eIF4F heterotrimeric initiation complex, which initiates mRNA translation and protein synthesis of a wide array of targets, including cyclinD1 and MMP-9 ([@bib94]). Pretreatment with rapamycin or cycloheximide abolishes CCL5-induced up-regulation of cyclin D1 and MMP-9 while also significantly reducing CCL5-mediated T cell chemotaxis ([@bib94]). Thus, S6K1 and 4E-BP1 seem to independently regulate the expression and activity of MMP-9 during migration. Finally, recent studies suggest that rapamycin inhibits the expression and activity of the small GTP-binding proteins RhoA, Cdc42, and Rac1 in a panel of tumor cells including Rh30, HeLa (cervical cancer), PC-3 (prostate cancer), Rh1 (Ewing sarcoma), and U373 (glioblastoma) cells ([@bib81]). Similar effects were observed by the expression of constitutively active 4EBP1-5A or the down-regulation of S6K1. Notably, overexpression of constitutively active RhoA, but not Rac1 and Cdc42, prevented the rapamycin-mediated inhibition of lamellipodia formation and cell migration ([@bib81]). Thus, in these cell lines, mTORC1-mediated regulation of cell motility depends on RhoA in a 4E-BP1-- and S6K1-dependent fashion.

mTORC1 has also been implicated as a regulator of tumor cell metastasis and angiogenesis in a variety of cancers ([@bib38]; [@bib83]; [@bib12]; [@bib128]; [@bib67]). The effects of rapamycin on metastasis have been linked to changes in VEGF, a key regulator of both metastasis and angiogenesis ([@bib31]; [@bib126]). Rapamycin treatment significantly inhibits the secretion of VEGF both in cultured mouse colon adenocarcinoma cells as well as adenocarcinoma tumor-bearing mice ([@bib38]). In B13LM cells (a lymphatic metastasis-prone pancreatic tumor cell line), dose-dependent reductions of VEGF-A and VEGF-C expression were observed after rapamycin treatment ([@bib67]). Further, in renal and nonsmall lung cancer cells, after treatment with rapamycin, a reduction in both VEGF-A and TGF-β expression were observed at both the mRNA and protein levels ([@bib83]; [@bib12]). Moreover, treatment of tumor-bearing mice with rapamycin gives rise to a significant reduction in the circulating levels of TGF-β ([@bib12]). These mechanistic studies suggest that mTORC1-regulated tumor metastasis and angiogenesis are associated with, at least in part, the production of VEGF and TGF-β.

TORC2 and cell migration
========================

TORC2 regulates cytoskeleton organization.
------------------------------------------

Accumulating evidence indicates that TORC2 is a key regulator of the actin cytoskeleton ([Fig. 2](#fig2){ref-type="fig"}). In *Saccharomyces cerevisiae*, TORC2 is required for the cell cycle--dependent polarization of the actin cytoskeleton ([@bib112]). In *Dictyostelium discoideum*, knockout of individual TORC2 components leads to the loss of cell polarity and the random extension of pseudopods from multiple points of the cells ([@bib20]; [@bib76], [@bib77]). In human neutrophils, inhibition of mTORC2 function by Rictor knockdown also leads to cell polarity defects and uniform cortical F-actin accumulation ([@bib80]). Although no obvious alterations in the actin cytoskeleton is observed in embryonic fibroblasts derived from Rictor knockout mice ([@bib39]; [@bib116]), siRNA-mediated knockdown of mTOR, Rictor, or mLST8 prevents actin polymerization and cell spreading in NIH3T3 fibroblasts ([@bib53]). In contrast, in HeLa cells, lentivirus shRNA-mediated Rictor and mTOR knockdown leads to increased stress fiber and cytoplasmic paxillin patch formation ([@bib109]). Together, these studies highlight the possibility that mTORC2 may have distinct effects on the actin cytoskeleton in different cell types.

The molecular mechanism by which TORC2 mediates actin reorganization has been extensively studied in *Saccharomyces cerevisiae* where the protein kinases PKC1, YPK2 (yeast protein kinase 2), and SLM (synthetic lethal with *Mss4*) are involved ([Fig. 2](#fig2){ref-type="fig"}). In these cells, TOR2 activates the GTP-binding protein Rho1 through the GTP exchange factor Rom2, which in turn triggers the activation of PKC1. Active PKC1 controls the polarization of the actin cytoskeleton via the MAP kinase cascade ([@bib58], [@bib59]; [@bib113]; [@bib82]), and up-regulation of Rho1, PKC1, or PKC1-controlled MAP kinase suppresses the actin defect of *tor2* mutant ([@bib44]). YPK2 is an AGC kinase that is directly activated by TORC2 via phosphorylation on Ser641 and Thr659 ([@bib60]). YPK2 activity is greatly reduced in *tor2* mutants and overexpression of a constitutively active mutant of YPK2 restores MAP kinase activation and suppresses the actin cytoskeleton organization defects of *tor2* mutants ([@bib60]). SLM1 and SLM2, homologous pleckstrin homology (PH) domain--containing proteins that bind to phosphatidylinositol-4,5-bisphosphate (PIP~2~), physically interact with AVO2 and BIT61 and mediate TORC2 signaling to the actin cytoskeleton ([@bib29]). Overexpression of PKC1, but not activated forms of the MAP kinase components can restore proper actin filament assembly and actin polarization in *slm1/slm2*-null cells ([@bib29]). Thus, SLM signaling likely involves a MAP kinase--independent PKC1 signaling branch or may act in a pathway that has an overlapping function with PKC1.

![**TORC2 regulates cytoskeleton organization and cell migration in yeast, amoebae, and mammalian cells.** (A) In *Saccharomyces cerevisiae*, TOR2 regulates actin organization and polarization through PKC1 and MAPK pathways. (B) In *Dictyostelium discoideum*, GPCRs specifically regulate TORC2 through a Ras signaling complex, which controls actin assembly and polarization as well as the synthesis of cAMP and the activation of PKA. (C) In mammalian cells, mTORC2 also regulates Rac and PKC and plays a key role in neutrophil chemotaxis by independently regulating F-actin polarization and myosin II phosphorylation. In endothelial cells, mTORC2 decreases p27^Kip1^ levels, which results in high RhoA activity and increased chemotaxis.](JCB_201102090_RGB_Fig2){#fig2}

Consistent with studies from yeast, mTORC2 also regulates the activation of PKC-α and Rac ([Fig. 2](#fig2){ref-type="fig"}). In HeLa cells, PKC-α activity is reduced in Rictor and mTOR knockdown cells and the morphology of the actin cytoskeleton in PKC-α knockdown cells is similar to that of Rictor knockdown cells ([@bib109]). In NIH3T3 cells, knockdown of mTOR, LST8, or Rictor results in a 20--30% decrease Rac1 activity. In addition, the expression of an active form of Rac1 or RhoA restores the formation of membrane ruffles, lamellipodia, and stress fibers in mTOR, mLST8, or Rictor knockdown cells ([@bib53]). The mechanism by which this occurs could involve P-Rex1 and P-Rex2 (PIP~3~-dependent Rac exchange factor), Rac GEFs linking GPCRs, Gβγ, and PI3K signaling to Rac activation. In HeLa cells, exogenously expressed P-Rex1 and P-Rex2 interact with mTOR through their tandem DEP (disheveled, EGL-10, and pleckstrin) domain ([@bib45]). Moreover, P-Rex1 appears to link mTOR signaling to Rac activation, as cells expressing dominant-negative constructs or shRNA-mediated knockdown of P-Rex1 specifically decrease mTORC2-dependent leucine-induced activation of Rac ([@bib45]). As the yeast Rom2 also harbors a DEP domain, P-Rex may represent the mammalian orthologue of Rom2.

TORC2 regulates cell migration.
-------------------------------

The ability of mTORC2 to regulate actin networks suggests that it may be involved in regulating cell migration. Although several studies on glioblastoma cells lines, Rh30, HeLa, and endothelial cells have implicated mTORC2 as a positive regulator of cell motility ([@bib78]; [@bib45]; [@bib86]; [@bib23]), in-depth mechanistic insight has come from studies in *Dictyostelium discoideum* ([Fig. 2](#fig2){ref-type="fig"}). In this system, the binding of the chemoattractant cAMP to specific GPCRs leads to the activation of signal transduction pathways that regulate gene expression, the production and degradation of cAMP, and chemotaxis ([@bib7]). Null mutations of TORC2 components give rise to cells with severe cell polarity defects, reduced chemotactic speeds and directionality, and the inability to activate adenylyl cyclase ([@bib20]; [@bib76], [@bib77]). Through a Ras signaling complex that activates RasC, chemoattractant addition stimulates TORC2 specifically at the leading edge of chemotaxing cells ([@bib17]; [@bib18]). TORC2 phosphorylates PKBA as well as PKBR1. Unlike PKBA, which harbors a PH domain, PKBR1 lacks a PH domain and is constitutively anchored to the plasma membrane (independently of PI3K activity) via a Myr site at its N terminus ([@bib89]; [@bib61]). Interestingly, PKBR1 appears to be the major effector of TORC2 during chemotaxis toward cAMP, as cells lacking PKBA show mild chemotaxis defects and retain a normal phosphorylation pattern of PKB substrates in aggregating cells. On the other hand, cells lacking PKBR1, or components of the Ras signaling complex, have a similar phenotype as TORC2 mutants, exhibiting both chemotaxis and adenylyl cyclase activity defects during aggregation ([@bib61]; [@bib17]). Once activated, PKBR1 phosphorylates several substrates, including Sca1, Talin, two Ras GEFs, and a Rho GAP ([@bib61]; [@bib18]). Although P-Sca1 has been shown to negatively regulate RasC activity, the precise role of the phosphorylation of other PKBR1 substrates during chemotaxis remains to be determined. Together, these studies establish a pathway arising from GPCRs, through G proteins and a Ras signaling complex, which activates TORC2 to regulate cell polarity, actin assembly, and adenylyl cyclase activity.

mTORC2 also plays a key role during neutrophil chemotaxis by independently regulating F-actin polarization and myosin II (MyoII) phosphorylation. Rictor knockdown or prolonged rapamycin treatment strongly inhibits neutrophil polarity and chemotaxis to the GPCR ligands fMLP (*N*-formyl-methionine-leucine-phenylalanine) and LTB~4~ (leukotriene B~4~), as well as cAMP production ([@bib80]). However, in contrast to *Dictyostelium discoideum*, the effects of mTORC2 are not mediated through Akt (PKB). Instead, and in accordance with findings in yeast and mammalian systems, it appears that PKC is mediating part of mTORC2's effects by regulating adenylyl cyclase activity and cAMP production. Cyclic AMP then regulates MyoII assembly through a RhoA/ROCK-dependent pathway. Interestingly, although mTORC1 is required for GM-CSF (granulocyte macrophage colony-stimulating factor)--induced neutrophil migration ([@bib37]; [@bib80]), it is dispensable for fMLP- and LTB~4~-mediated chemotaxis ([@bib80]). Thus, mTORC2 appears to specifically regulate neutrophil chemotaxis toward GPCR ligands. Similarly to neutrophils, in mouse bone marrow--derived mast cells, the GPCR-mediated chemotaxis via prostaglandin E~2~ (PGE~2~) receptors is specifically dependent on mTORC2 ([@bib70]). Rictor-targeted shRNA results in a significant attenuation in PGE~2~-mediated chemotaxis, yet the selective inhibition of mTORC1 by rapamycin treatment or by Raptor knockdown fails to decrease PGE~2~-mediated chemotaxis in these cells.

Rictor levels are elevated in a wide array of glioma cell lines and primary glioma tumor cells ([@bib86]), as well as in invasive breast ductal carcinomas ([@bib138]). Furthermore, overexpression or knockdown of Rictor in glioma cell lines results in either increased or decreased cell migration, ([@bib86]), although a separate group reported that mTORC2 negatively regulates invasion in two glioma cell lines ([@bib25]). Intriguingly, Rictor could mediate its effects on cell migration in an mTORC2-independent fashion. Indeed, [@bib138] present evidence suggesting that the inhibition of migration observed in MDA-MB-231 breast cancer cells with reduced Rictor levels is mediated independently of mTORC2 through a direct interaction with PKC-ζ. They show that mSin1 knockdown does not alter chemotaxis of MDA-MB-231 cells, nor does it affect Rictor--PKC-ζ interaction ([@bib138]). In this context, Rictor can form a complex with the integrin-linked kinase and regulate Akt phosphorylation in an mTORC2-independent fashion ([@bib87]). It will be interesting to see if these mTORC2-independent effects of Rictor impact mTORC2 or even mTORC1 signals.

Although rapamycin FKBP12 cannot bind to mTORC2, prolonged rapamycin treatment inhibits mTORC2 function by sequestering mTOR and interfering with mTORC2 assembly in some cell lines ([@bib111]). Surprisingly, prolonged but not short-term rapamycin treatment inhibits endothelial cell ([@bib120]) as well as mesangial cell migration ([@bib24]) through the cyclin-dependent kinase inhibitor (p27^Kip1^). A recent study revealed that siRNA knockdown of Rictor increases p27^Kip1^ levels, resulting in the inhibition of RhoA activity and inhibition of VEGF-mediated endothelial chemotaxis ([@bib93]). These findings provide novel mechanistic insight into the role of cyclin-dependent kinase proteins outside the nucleus ([@bib26]).

Perspectives
============

Although it is becoming clear that both TOR complex 1 and 2 regulate cytoskeletal networks and cell migration, we are far from understanding the mechanism by which this takes place. This is primarily due to the complexity of the TOR signaling cascades and their impact on a wide array of effectors, as well as to the distinct migratory behaviors exhibited by different cells and the chemotactic input (i.e., RTK vs. GPCR). In this context, it will be very interesting to see if the TORC2-mediated effects on chemotaxis of amoeboid-like cells extend to other cell types with distinct cellular architecture and motility behaviors. Indeed, in contrast to mesenchymal cells such as fibroblasts, where microtubules primarily extend to the front ([@bib72]; [@bib40]), amoeboid-like cells such *Dictyostelium discoideum*, neutrophils, and migrating lymphocytes have an extensive microtubule network at their back and the microtubule organizing center is positioned behind the nucleus ([@bib104]; [@bib28]; [@bib69]). This distinct cellular architecture underscores the dramatically different mechanisms regulating the motility machinery in these two cell types. Indeed, in contrast to neutrophils where RhoA activity is restricted to the back ([@bib133]), high RhoA activity has been reported at the leading edge of HeLa and MDCK cells ([@bib73]) and Rho signaling has been shown to stabilize microtubules at the leading edge of fibroblast cells ([@bib96]). It is therefore foreseeable that distinct TOR signals mediate distinct effects on cell types with very different cytoskeletal organizations and motility machineries. This could have interesting consequences during metastasis, where dynamic epithelial-to-mesenchymal as well as mesenchymal-to-amoeboid transitions dramatically alter the motility behavior of cells ([@bib33]). Importantly, as it has been observed with the PI3K pathway ([@bib30]), the effects of TOR signaling may also be dependent on the microenvironment, which adds another layer of complexity to the picture. In any case, to move the field forward, it is important to use approaches that precisely target TORC1 or TORC2. Although rapamycin certainly represents a powerful tool in the TOR field, in an increasing number of cells, long-term treatment with rapamycin also inhibits TORC2 ([@bib111]; [@bib80]; [@bib93]). We have yet to fully appreciate the extent by which TOR complexes regulate a wide array of processes, including cell migration, and the future will undoubtedly continue to bring unexpected insight.
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